Clinical Trials
15 trialsNCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT00887146 2026-01-22
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
Alliance for Clinical Trials in Oncology
Phase 3 Active not recruiting
NCT06177964 2025-08-17
Lerapolturev (PVSRIPO) in GBM
Duke University
Phase 2 Recruiting
NCT07120984 2025-08-13
IMAGLIO
Philogen S.p.A.
Phase 2 Not yet recruiting
NCT02986178 2025-07-11
Lerapolturev in Recurrent Malignant Glioma
Istari Oncology, Inc.
Phase 2 Completed
NCT01682187 2024-11-07
A Dose-Escalation Study in Participants With Recurrent Malignant Glioma
Eli Lilly and Company
Phase 1 Completed
NCT02796261 2022-01-21
STELLAR
Orbus Therapeutics, Inc.
Phase 3 Unknown
NCT02678975 2021-03-18
Disulfiram in Recurrent Glioblastoma
Sahlgrenska University Hospital
Phase 2/3 Completed
NCT00004259 2019-09-12
Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00002569 2018-06-18
Radiation Therapy With or Without Chemotherapy in Treating Patients With Anaplastic Oligodendroglioma
Radiation Therapy Oncology Group
Phase 3 Completed
NCT01989052 2016-08-04
Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma
Duke University
Phase 1 Terminated
NCT02333513 2015-04-09
A Study to Evaluate the Safety and Effectiveness of PCV Chemotherapy in Patients With Recurrent High-grade Glioma With IDH1/2 Mutation
Hebei Yanda Hospital
Phase NA Unknown
NCT00005796 2015-03-25
Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors
Indiana University
Phase 1 Completed
NCT00761280 2014-11-14
SAPPHIRE
Isarna Therapeutics GmbH
Phase 3 Terminated
NCT00002840 2012-07-10
Radiation Therapy With and Without Combination Chemotherapy in Patients With Resected Anaplastic Oligodendroglioma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Completed